Medacta International SA appears in FDA device records as the applicant for knee arthroplasty submissions reviewed under the orthopedic advisory committee. The supplied filings place the company in Class II knee prosthesis regulation, with product codes JWH, MBH and KRO appearing across submissions. The documented record spans a 2014 GMK Total Knee System clearance, a 2021 GMK Revision & Hinge Extension with TiNbN coating, a February 2026 GMK 3D Metal Tibial Tray Extension, and a September 2026 GMK Extension. The most recent entry, K262057, was received June 18, 2026 and decided September 15, 2026 as substantially equivalent. [1][2][5][6][4]
The GMK Extension clearance
K262057 covers the device named GMK Extension, a knee joint patellofemorotibial polymer/metal/polymer semi-constrained cemented prosthesis under 21 CFR 888.3560, Class II, product code JWH. The FDA record lists Medacta International SA as applicant at Strada Regina, Castel San Pietro, Switzerland, with a Traditional 510(k) pathway, a Summary statement, and no third-party review. The decision description is Substantially Equivalent, dated September 15, 2026. [1][2]
The determination document identifies the subject devices as GMK Sphere FULL PE FLEX and FLEX E-CROSS Tibias and names predicate devices K131310, K202022, K090988 and K211004. Substantial equivalence is stated with respect to design, articular surface, size, configuration, thickness, material, radiopaque markers and cement pockets. These are the compared characteristics as written in the FDA letter. [2]
Earlier knee submissions
K142069, dated October 1, 2014 and received October 2, 2014, covers the GMK Total Knee System under 21 CFR 888.3560, Class II, product code JWH. The FDA letter addresses Medacta International through a regulatory contact in Chicago, Illinois. The document states that the GMK Extension can be considered substantially equivalent to its predicate devices. [5]
K210010, dated March 2, 2021, covers the GMK Revision & Hinge Extension - TiNbN Coating under 21 CFR 888.3510 and 21 CFR 888.3560, Class II, with product codes KRO and JWH. The submission lists Stefano Baj as Regulatory and Compliance Director at Medacta International SA and Chris Lussier as applicant correspondent at Medacta USA. The device is classified as a total knee prosthesis. [6]
K253328, dated February 26, 2026, covers the GMK 3D Metal Tibial Tray Extension under 21 CFR 888.3565 and 21 CFR 888.3560, Class II, product codes MBH and JWH. Substantial equivalence is claimed to the GMK 3D Metal Tibial Tray, K221850, also attributed to Medacta International SA. [4]
Published product material
Medacta's own surgical technique document states that the GMK Revision System includes GMK Revision and GMK Hinge, indicated for total knee replacement primary or revision surgeries in the presence of collateral ligament deficiency from moderate to serious and/or bone loss. The same document lists reasons total knee arthroplasties may fail, including polyethylene wear, aseptic loosening, osteolysis, infection, ligamentous instability and patello-femoral complications. It is published by Medacta International SA in Castel San Pietro, Switzerland, and is intended for the US market. [8]
Medacta's GMK Primary page states that the system was conceived in 2003 as a knee replacement system designed around the natural anatomy and kinematics of the knee joint, and describes an asymmetric tibial tray intended to improve coverage of the tibial surface. The company's resource library lists a GMK Revision System brochure and a GMK Sphere leaflet among downloadable documents. These are company-published descriptions, not FDA findings. [9][7]
What the record does and does not establish
The supplied collection contains one linked 510(k) record, K262057, with a single SESE decision, and the record sample contains that same entry. These counts describe the supplied filings as of the snapshot date and are not measures of total company sales, total portfolio or safety performance. No recall records appear in the supplied sample. [1]
The filings identify Medacta International SA as applicant and Medacta USA personnel as correspondents on some submissions. No parent, ownership structure or brand relationship beyond those named entities is verified in the public documents, and no headquarters should be inferred from filing addresses. Commercial availability, clinical outcomes and certifications are not established here. [2][6][5]
